Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient

N/ANo Longer AvailableNCT02090127

AVEO Pharmaceuticals, Inc.

Overview

This treatment protocol will serve as a mechanism to continue to provide ficlatuzumab to patient 0001-000412, who was previously enrolled under protocol P05538 and whom the investigator believes is deriving clinical benefit from ficlatuzumab treatment.

Study Type

EXPANDED_ACCESS

Conditions

Mullerian Mixed Tumor of Ovary

Interventions

ficlatuzumabDRUG

humanized anti-hepatocyte growth factor (HGF) monoclonal antibody IV administration at 16.5mg/kg every 2 weeks with a ±2 day window around dosing dates, as long as subject is deriving clinical benefit as determined by the Investigator

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Per original P05538 protocol Exclusion Criteria: * Per original P05538 protocol

Locations (1)

START

San Antonio, Texas, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.